Unilife Corp. (NASDAQ: UNIS; Stock Twits: $UNIS) is a U.S. based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities inPennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.
Unilife has been upgraded from "sell" to "hold" with a price target of $3 by MLV & Co, a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. See other analyst stock upgrades at Nasdaq.com.